News >

Pembrolizumab Combo Fails in Melanoma

Jason M. Broderick @jasoncology
Published: Friday, Apr 06, 2018

Dr. Roy Baynes

Roy Baynes, MD, PhD
The combination of the PD-1 inhibitor pembrolizumab (Keytruda) and the IDO1 inhibitor epacadostat failed to improve progression-free survival (PFS) versus single-agent pembrolizumab in patients with unresectable or metastatic melanoma, according to findings from the phase III ECHO-301/KEYNOTE-252 trial.

Among adverse events of special interest, hypothyroidism and severe skin reactions occurred in 4 patients each, colitis and uveitis in 2 each, and autoimmune hepatitis in 1 patient. Grade 3/4 adverse events of interest consisted of 3 cases of severe skin reaction, 2 of colitis, and 1 of autoimmune hepatitis.
Hamid O, Gajewski TF, Frankel AE, et al. Epacadostat plus pembrolizumab in patients with advanced melanoma: Phase 1 and 2 efficacy and safety results from ECHO-202/ KEYNOTE-037. n: Proceedings from the 2017 ESMO Congress; September 8-12, 2017; Madrid, Spain. Abstract 1214O.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication